DLX vs QUAD vs ENVA vs SRPT

For growth investors, Enova International, Inc.

(ENVA) is the stronger pick with 18. 6% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). Quad/Graphics, Inc. (QUAD) offers the better valuation at 14. 2x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate Deluxe Corporation (DLX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Quad/Graphics, Inc.

(QUAD) is the cheapest at 14. 2x versus Deluxe Corporation at 14. 9x. On forward P/E, Quad/Graphics, Inc. is actually cheaper at 6. 3x.

Over the past 5 years, Enova International, Inc.

(ENVA) delivered a total return of +368. 1%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: ENVA returned +20. 3% versus DLX's -38. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quad/Graphics, Inc.

(QUAD) is the lower-risk stock at 1. 03β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 97% more volatile than QUAD relative to the S&P 500. On balance sheet safety, Sarepta Therapeutics, Inc. (SRPT) carries a lower debt/equity ratio of 91% versus 3% for Quad/Graphics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Enova International, Inc.

(ENVA) is pulling ahead at 18. 6% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: Quad/Graphics, Inc. grew EPS 150. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Enova International, Inc.

(ENVA) is the more profitable company, earning 9. 8% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 9. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENVA leads at 23. 5% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Quad/Graphics, Inc.

(QUAD) trades at 6. 3x forward P/E versus 10. 5x for Enova International, Inc. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SRPT: 18. 4% to $24. 63.

In this comparison, DLX (4.

5% yield), QUAD (3. 8% yield) pay a dividend. ENVA, SRPT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Quad/Graphics, Inc.

(QUAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), 3. 8% yield). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QUAD: -23. 3%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DLX (Communication Services) and QUAD (Industrials) and ENVA (Financial Services) and SRPT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DLX is a small-cap deep-value stock; QUAD is a small-cap deep-value stock; ENVA is a small-cap high-growth stock; SRPT is a small-cap high-growth stock. DLX, QUAD pay a dividend while ENVA, SRPT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.